Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.

Seddon, B., Strauss, S.J., Whelan, J. et al. (16 more authors) (2017) Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. The Lancet Oncology, 18 (10). pp. 1397-1410. ISSN 1470-2045

Abstract

Metadata

Authors/Creators:
  • Seddon, B.
  • Strauss, S.J.
  • Whelan, J.
  • Leahy, M.
  • Woll, P.J. https://orcid.org/0000-0002-1118-0831
  • Cowie, F.
  • Rothermundt, C.
  • Wood, Z.
  • Benson, C.
  • Ali, N.
  • Marples, M.
  • Veal, G.J.
  • Jamieson, D.
  • Küver, K.
  • Tirabosco, R.
  • Forsyth, S.
  • Nash, S.
  • Dehbi, H-M.
  • Beare, S.
Copyright, Publisher and Additional Information: © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Dates:
  • Accepted: 12 July 2017
  • Published (online): 4 September 2017
  • Published: October 2017
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > Department of Oncology (Sheffield)
Depositing User: Symplectic Sheffield
Date Deposited: 06 Oct 2017 14:44
Last Modified: 06 Oct 2017 14:44
Published Version: https://doi.org/10.1016/S1470-2045(17)30622-8
Status: Published
Publisher: Elsevier
Refereed: Yes
Identification Number: https://doi.org/10.1016/S1470-2045(17)30622-8
Related URLs:

Share / Export

Statistics